Skip to main content
Top
Published in: BMC Immunology 1/2012

Open Access 01-12-2012 | Research article

Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications

Authors: Miriam I Jimenez-Perez, Luis F Jave-Suarez, Pablo C Ortiz-Lazareno, Alejandro Bravo-Cuellar, Oscar Gonzalez-Ramella, Adriana Aguilar-Lemarroy, Georgina Hernandez-Flores, Ana L Pereira-Suarez, Adrian Daneri-Navarro, Susana del Toro-Arreola

Published in: BMC Immunology | Issue 1/2012

Login to get access

Abstract

Background

Cervical cancer represents the third most commonly diagnosed cancer and the fourth leading cause of cancer-related deaths in women worldwide. Natural killer (NK) cells play an important role in the defense against viruses, intracellular bacteria and tumors. NKG2D, an activating receptor on NK cells, recognizes MHC class I chain-related molecules, such as MICA/B and members of the ULBP/RAET1 family. Tumor-derived soluble NKG2D-ligands have been shown to down-modulate the expression of NKG2D on NK cells. In addition to the down-modulation induced by soluble NKG2D-ligands, it has recently been described that persistent cell-cell contact can also down-modulate NKG2D expression. The goal of this study was to determine whether the NKG2D receptor is down-modulated by cell-cell contact with cervical cancer cells and whether this down-modulation might be associated with changes in NK cell activity.

Results

We demonstrate that NKG2D expressed on NKL cells is down-modulated by direct cell contact with cervical cancer cell lines HeLa, SiHa, and C33A, but not with non-tumorigenic keratinocytes (HaCaT). Moreover, this down-modulation had functional implications. We found expression of NKG2D-ligands in all cervical cancer cell lines, but the patterns of ligand distribution were different in each cell line. Cervical cancer cell lines co-cultured with NKL cells or fresh NK cells induced a marked diminution of NKG2D expression on NKL cells. Additionally, the cytotoxic activity of NKL cells against K562 targets was compromised after co-culture with HeLa and SiHa cells, while co-culture with C33A increased the cytotoxic activity of the NKL cells.

Conclusions

Our results suggest that differential expression of NKG2D-ligands in cervical cancer cell lines might be associated with the down-modulation of NKG2D, as well as with changes in the cytotoxic activity of NKL cells after cell-cell contact with the tumor cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.PubMedCrossRef
2.
go back to reference zur Hausen H: Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996, 1288 (2): F55-F78.PubMed zur Hausen H: Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996, 1288 (2): F55-F78.PubMed
3.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189 (1): 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.PubMedCrossRef Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189 (1): 12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.PubMedCrossRef
4.
go back to reference Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006, 110 (5): 525-541.CrossRef Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006, 110 (5): 525-541.CrossRef
5.
7.
go back to reference Li C, Houser BL, Nicotra ML, Strominger JL: HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci USA. 2009, 106 (14): 5767-5772. 10.1073/pnas.0901173106.PubMedPubMedCentralCrossRef Li C, Houser BL, Nicotra ML, Strominger JL: HLA-G homodimer-induced cytokine secretion through HLA-G receptors on human decidual macrophages and natural killer cells. Proc Natl Acad Sci USA. 2009, 106 (14): 5767-5772. 10.1073/pnas.0901173106.PubMedPubMedCentralCrossRef
8.
go back to reference Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G: Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol. 1998, 161 (11): 5821-5824.PubMed Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G: Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol. 1998, 161 (11): 5821-5824.PubMed
9.
go back to reference Babu S, Blauvelt CP, Nutman TB: Filarial parasites induce NK cell activation, type 1 and type 2 cytokine secretion, and subsequent apoptotic cell death. J Immunol. 2007, 179 (4): 2445-2456.PubMedCrossRef Babu S, Blauvelt CP, Nutman TB: Filarial parasites induce NK cell activation, type 1 and type 2 cytokine secretion, and subsequent apoptotic cell death. J Immunol. 2007, 179 (4): 2445-2456.PubMedCrossRef
10.
go back to reference Marcenaro E, Della Chiesa M, Bellora F, Parolini S, Millo R, Moretta L, Moretta A: IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol. 2005, 174 (7): 3992-3998.PubMedCrossRef Marcenaro E, Della Chiesa M, Bellora F, Parolini S, Millo R, Moretta L, Moretta A: IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol. 2005, 174 (7): 3992-3998.PubMedCrossRef
11.
go back to reference Waldhauer I, Steinle A: NK cells and cancer immunosurveillance. Oncogene. 2008, 27 (45): 5932-5943. 10.1038/onc.2008.267.PubMedCrossRef Waldhauer I, Steinle A: NK cells and cancer immunosurveillance. Oncogene. 2008, 27 (45): 5932-5943. 10.1038/onc.2008.267.PubMedCrossRef
12.
go back to reference Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 2011, 331 (6013): 44-49. 10.1126/science.1198687.PubMedPubMedCentralCrossRef Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 2011, 331 (6013): 44-49. 10.1126/science.1198687.PubMedPubMedCentralCrossRef
13.
go back to reference Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001, 14 (2): 123-133. 10.1016/S1074-7613(01)00095-4.PubMedCrossRef Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001, 14 (2): 123-133. 10.1016/S1074-7613(01)00095-4.PubMedCrossRef
14.
go back to reference Eagle RA, Trowsdale J: Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007, 7 (9): 737-744. 10.1038/nri2144.PubMedCrossRef Eagle RA, Trowsdale J: Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007, 7 (9): 737-744. 10.1038/nri2144.PubMedCrossRef
15.
go back to reference Zwirner NW, Dole K, Stastny P: Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol. 1999, 60 (4): 323-330. 10.1016/S0198-8859(98)00128-1.PubMedCrossRef Zwirner NW, Dole K, Stastny P: Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol. 1999, 60 (4): 323-330. 10.1016/S0198-8859(98)00128-1.PubMedCrossRef
16.
go back to reference Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Mullberg J, Rousseau AM, Ulrich D, Armitage R: ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol. 2001, 31 (5): 1428-1437. 10.1002/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4.PubMedCrossRef Kubin M, Cassiano L, Chalupny J, Chin W, Cosman D, Fanslow W, Mullberg J, Rousseau AM, Ulrich D, Armitage R: ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol. 2001, 31 (5): 1428-1437. 10.1002/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4.PubMedCrossRef
17.
go back to reference Conejo-Garcia JR, Benencia F, Courreges MC, Khang E, Zhang L, Mohamed-Hadley A, Vinocur JM, Buckanovich RJ, Thompson CB, Levine B: Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther. 2003, 2 (4): 446-451.PubMedCrossRef Conejo-Garcia JR, Benencia F, Courreges MC, Khang E, Zhang L, Mohamed-Hadley A, Vinocur JM, Buckanovich RJ, Thompson CB, Levine B: Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther. 2003, 2 (4): 446-451.PubMedCrossRef
18.
go back to reference Bacon L, Eagle RA, Meyer M, Easom N, Young NT, Trowsdale J: Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol. 2004, 173 (2): 1078-1084.PubMedCrossRef Bacon L, Eagle RA, Meyer M, Easom N, Young NT, Trowsdale J: Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol. 2004, 173 (2): 1078-1084.PubMedCrossRef
19.
go back to reference Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V: Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 2008, 8: 16-10.1186/1471-2407-8-16.PubMedPubMedCentralCrossRef Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V: Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 2008, 8: 16-10.1186/1471-2407-8-16.PubMedPubMedCentralCrossRef
20.
go back to reference Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC: Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B. Clin Cancer Res. 2009, 15 (16): 5208-5215. 10.1158/1078-0432.CCR-09-0886.PubMedCrossRef Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC: Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B. Clin Cancer Res. 2009, 15 (16): 5208-5215. 10.1158/1078-0432.CCR-09-0886.PubMedCrossRef
21.
go back to reference Song H, Kim J, Cosman D, Choi I: Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol. 2006, 239 (1): 22-30. 10.1016/j.cellimm.2006.03.002.PubMedCrossRef Song H, Kim J, Cosman D, Choi I: Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol. 2006, 239 (1): 22-30. 10.1016/j.cellimm.2006.03.002.PubMedCrossRef
22.
go back to reference Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L: Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One. 2011, 6 (2): e16899-10.1371/journal.pone.0016899.PubMedPubMedCentralCrossRef Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L: Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One. 2011, 6 (2): e16899-10.1371/journal.pone.0016899.PubMedPubMedCentralCrossRef
23.
go back to reference Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, Vales-Gomez M, Reyburn HT: Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010, 70 (2): 481-489. 10.1158/0008-5472.CAN-09-1688.PubMedPubMedCentralCrossRef Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, Vales-Gomez M, Reyburn HT: Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010, 70 (2): 481-489. 10.1158/0008-5472.CAN-09-1688.PubMedPubMedCentralCrossRef
24.
go back to reference Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z: Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008, 180 (11): 7249-7258.PubMedCrossRef Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z: Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008, 180 (11): 7249-7258.PubMedCrossRef
25.
go back to reference Hedlund M, Stenqvist A-C, Nagaeva O, Kjellberg L, Wulff M, Baranov V, Mincheva-Nilsson L: Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol. 2009, 183 (1): 340-351. 10.4049/jimmunol.0803477.PubMedCrossRef Hedlund M, Stenqvist A-C, Nagaeva O, Kjellberg L, Wulff M, Baranov V, Mincheva-Nilsson L: Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol. 2009, 183 (1): 340-351. 10.4049/jimmunol.0803477.PubMedCrossRef
26.
go back to reference Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I: Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immun. 2009, 58 (5): 641-652.CrossRef Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I: Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immun. 2009, 58 (5): 641-652.CrossRef
27.
go back to reference von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, Glasmacher A, Märten A, Schmidt-Wolf I, Brossart P: Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immun. 2010, 59 (6): 829-839.CrossRef von Lilienfeld-Toal M, Frank S, Leyendecker C, Feyler S, Jarmin S, Morgan R, Glasmacher A, Märten A, Schmidt-Wolf I, Brossart P: Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked. Cancer Immunol Immun. 2010, 59 (6): 829-839.CrossRef
28.
go back to reference Maccalli C, Nonaka D, Piris A, Pende D, Rivoltini L, Castelli C, Parmiani G: NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res. 2007, 13 (24): 7459-7468. 10.1158/1078-0432.CCR-07-1166.PubMedCrossRef Maccalli C, Nonaka D, Piris A, Pende D, Rivoltini L, Castelli C, Parmiani G: NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients. Clin Cancer Res. 2007, 13 (24): 7459-7468. 10.1158/1078-0432.CCR-07-1166.PubMedCrossRef
29.
go back to reference Wu JD, Atteridge CL, Wang X, Seya T, Plymate SR: Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res. 2009, 15 (2): 632-640. 10.1158/1078-0432.CCR-08-1305.PubMedPubMedCentralCrossRef Wu JD, Atteridge CL, Wang X, Seya T, Plymate SR: Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res. 2009, 15 (2): 632-640. 10.1158/1078-0432.CCR-08-1305.PubMedPubMedCentralCrossRef
30.
go back to reference Ebert EC, Groh V: Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology. 2008, 124 (1): 33-41. 10.1111/j.1365-2567.2007.02656.x.PubMedPubMedCentralCrossRef Ebert EC, Groh V: Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology. 2008, 124 (1): 33-41. 10.1111/j.1365-2567.2007.02656.x.PubMedPubMedCentralCrossRef
31.
go back to reference Allegra S, Deleine C, Michael-Jubely R, Gryson C, Boirie Y, Kantakamalakul W, Vasson MP: Implementation of the EGFP-K562 flow cytometric NK test: determination of NK cytotoxic activity in healthy elderly volunteers before and after feeding. Cytometry Part A: The journal of the International Society for Analytical Cytology. 2006, 69 (9): 992-998.CrossRef Allegra S, Deleine C, Michael-Jubely R, Gryson C, Boirie Y, Kantakamalakul W, Vasson MP: Implementation of the EGFP-K562 flow cytometric NK test: determination of NK cytotoxic activity in healthy elderly volunteers before and after feeding. Cytometry Part A: The journal of the International Society for Analytical Cytology. 2006, 69 (9): 992-998.CrossRef
32.
go back to reference El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE: The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007, 67 (18): 8444-8449. 10.1158/0008-5472.CAN-06-4230.PubMedCrossRef El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE: The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007, 67 (18): 8444-8449. 10.1158/0008-5472.CAN-06-4230.PubMedCrossRef
33.
go back to reference Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L: Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002, 62 (21): 6178-6186.PubMed Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L: Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002, 62 (21): 6178-6186.PubMed
34.
go back to reference Del Toro-Arreola S, Arreygue-Garcia N, Aguilar-Lemarroy A, Cid-Arregui A, Jimenez-Perez M, Haramati J, Barros-Nunez P, Gonzalez-Ramella O, Del Toro-Arreola A, Ortiz-Lazareno P: MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines. Cancer Cell Int. 2011, 11: 15-10.1186/1475-2867-11-15.PubMedPubMedCentralCrossRef Del Toro-Arreola S, Arreygue-Garcia N, Aguilar-Lemarroy A, Cid-Arregui A, Jimenez-Perez M, Haramati J, Barros-Nunez P, Gonzalez-Ramella O, Del Toro-Arreola A, Ortiz-Lazareno P: MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines. Cancer Cell Int. 2011, 11: 15-10.1186/1475-2867-11-15.PubMedPubMedCentralCrossRef
35.
go back to reference van den Broek MF, Hengartner H: The role of perforin in infections and tumour surveillance. Exp Physiol. 2000, 85 (6): 681-685. 10.1017/S0958067000020972.PubMedCrossRef van den Broek MF, Hengartner H: The role of perforin in infections and tumour surveillance. Exp Physiol. 2000, 85 (6): 681-685. 10.1017/S0958067000020972.PubMedCrossRef
36.
go back to reference Diefenbach A, Raulet DH: The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002, 188: 9-21. 10.1034/j.1600-065X.2002.18802.x.PubMedCrossRef Diefenbach A, Raulet DH: The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002, 188: 9-21. 10.1034/j.1600-065X.2002.18802.x.PubMedCrossRef
37.
go back to reference Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL: NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med. 1994, 180 (2): 537-543. 10.1084/jem.180.2.537.PubMedCrossRef Litwin V, Gumperz J, Parham P, Phillips JH, Lanier LL: NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J Exp Med. 1994, 180 (2): 537-543. 10.1084/jem.180.2.537.PubMedCrossRef
38.
go back to reference Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW: Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004, 104 (1): 170-177. 10.1182/blood-2003-12-4438.PubMedCrossRef Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW: Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004, 104 (1): 170-177. 10.1182/blood-2003-12-4438.PubMedCrossRef
39.
go back to reference Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaelsson J: Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood. 2010, 115 (6): 1166-1174. 10.1182/blood-2009-09-245746.PubMedCrossRef Fauriat C, Ivarsson MA, Ljunggren HG, Malmberg KJ, Michaelsson J: Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood. 2010, 115 (6): 1166-1174. 10.1182/blood-2009-09-245746.PubMedCrossRef
40.
go back to reference Yokoyama WM: The search for the missing 'missing-self' receptor on natural killer cells. Scand J Immunol. 2002, 55 (3): 233-237. 10.1046/j.1365-3083.2002.01054.x.PubMedCrossRef Yokoyama WM: The search for the missing 'missing-self' receptor on natural killer cells. Scand J Immunol. 2002, 55 (3): 233-237. 10.1046/j.1365-3083.2002.01054.x.PubMedCrossRef
41.
go back to reference Chalupny NJ, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D: ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun. 2003, 305 (1): 129-135. 10.1016/S0006-291X(03)00714-9.PubMedCrossRef Chalupny NJ, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D: ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun. 2003, 305 (1): 129-135. 10.1016/S0006-291X(03)00714-9.PubMedCrossRef
42.
go back to reference Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL: Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity. 2003, 18 (1): 41-51. 10.1016/S1074-7613(02)00505-8.PubMedCrossRef Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Bour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL: Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity. 2003, 18 (1): 41-51. 10.1016/S1074-7613(02)00505-8.PubMedCrossRef
43.
go back to reference Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR: NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol. 2009, 83 (23): 12345-12354. 10.1128/JVI.01175-09.PubMedPubMedCentralCrossRef Ashiru O, Bennett NJ, Boyle LH, Thomas M, Trowsdale J, Wills MR: NKG2D ligand MICA is retained in the cis-Golgi apparatus by human cytomegalovirus protein UL142. J Virol. 2009, 83 (23): 12345-12354. 10.1128/JVI.01175-09.PubMedPubMedCentralCrossRef
44.
go back to reference Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D: Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med. 2003, 197 (11): 1427-1439. 10.1084/jem.20022059.PubMedPubMedCentralCrossRef Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D: Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med. 2003, 197 (11): 1427-1439. 10.1084/jem.20022059.PubMedPubMedCentralCrossRef
45.
go back to reference Schepis D, D'Amato M, Studahl M, Bergström T, Kärre K, Berg L: Herpes simplex virus infection downmodulates nkg2d ligand expression. Scand J Immunol. 2009, 69 (5): 429-436. 10.1111/j.1365-3083.2009.02241.x.PubMedCrossRef Schepis D, D'Amato M, Studahl M, Bergström T, Kärre K, Berg L: Herpes simplex virus infection downmodulates nkg2d ligand expression. Scand J Immunol. 2009, 69 (5): 429-436. 10.1111/j.1365-3083.2009.02241.x.PubMedCrossRef
46.
go back to reference Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, Park JS: Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett. 2002, 179 (2): 205-212. 10.1016/S0304-3835(01)00871-0.PubMedCrossRef Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, Park JS: Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett. 2002, 179 (2): 205-212. 10.1016/S0304-3835(01)00871-0.PubMedCrossRef
47.
go back to reference Antonsson A, Payne E, Hengst K, McMillan NA: The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J Interferon Cytokine Res. 2006, 26 (7): 455-461. 10.1089/jir.2006.26.455.PubMedCrossRef Antonsson A, Payne E, Hengst K, McMillan NA: The human papillomavirus type 16 E7 protein binds human interferon regulatory factor-9 via a novel PEST domain required for transformation. J Interferon Cytokine Res. 2006, 26 (7): 455-461. 10.1089/jir.2006.26.455.PubMedCrossRef
48.
go back to reference Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ: Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem. 2000, 275 (10): 6764-6769. 10.1074/jbc.275.10.6764.PubMedCrossRef Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ: Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem. 2000, 275 (10): 6764-6769. 10.1074/jbc.275.10.6764.PubMedCrossRef
49.
go back to reference Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K: CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol. 2010, 84 (22): 11614-11623. 10.1128/JVI.01053-10.PubMedPubMedCentralCrossRef Miura S, Kawana K, Schust DJ, Fujii T, Yokoyama T, Iwasawa Y, Nagamatsu T, Adachi K, Tomio A, Tomio K: CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV. J Virol. 2010, 84 (22): 11614-11623. 10.1128/JVI.01053-10.PubMedPubMedCentralCrossRef
Metadata
Title
Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications
Authors
Miriam I Jimenez-Perez
Luis F Jave-Suarez
Pablo C Ortiz-Lazareno
Alejandro Bravo-Cuellar
Oscar Gonzalez-Ramella
Adriana Aguilar-Lemarroy
Georgina Hernandez-Flores
Ana L Pereira-Suarez
Adrian Daneri-Navarro
Susana del Toro-Arreola
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2012
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-13-7

Other articles of this Issue 1/2012

BMC Immunology 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine